Heerspink Hiddo J Lambers, Ninomiya Toshiharu, Zoungas Sophia, de Zeeuw Dick, Grobbee Diederick E, Jardine Meg J, Gallagher Martin, Roberts Matthew A, Cass Alan, Neal Bruce, Perkovic Vlado
George Institute for International Health, University of Sydney, Sydney, Australia.
Lancet. 2009 Mar 21;373(9668):1009-15. doi: 10.1016/S0140-6736(09)60212-9. Epub 2009 Feb 25.
Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefits of lowering blood pressure in the general population, there is uncertainty about the efficacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the effect of blood pressure lowering in patients on dialysis.
We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-analysis was done with a random effects model.
We identified eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. Weighted mean systolic blood pressure was 4.5 mm Hg lower and diastolic blood pressure 2.3 mm Hg lower in actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of cardiovascular events (RR 0.71, 95% CI 0.55-0.92; p=0.009), all-cause mortality (RR 0.80, 0.66-0.96; p=0.014), and cardiovascular mortality (RR 0.71, 0.50-0.99; p=0.044) than control regimens. The effects seem to be consistent across a range of patient groups included in the studies.
Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population.
接受透析的患者心血管疾病死亡率和发病率大幅增加。尽管多项试验已表明在普通人群中降低血压对心血管有益,但对于透析患者降低血压的疗效和耐受性仍存在不确定性。我们进行了一项系统评价和荟萃分析,以评估透析患者降低血压的效果。
我们系统检索了Medline、Embase和Cochrane图书馆数据库,以查找1950年至2008年11月期间报道的试验,无语言限制。我们从透析患者降低血压的随机对照试验中提取了标准化数据集,这些试验报告了心血管结局。采用随机效应模型进行荟萃分析。
我们确定了八项相关试验,这些试验提供了1679例患者和495例心血管事件的数据。积极治疗的患者加权平均收缩压比对照组低4.5 mmHg,舒张压低2.3 mmHg。与对照方案相比,降低血压治疗与心血管事件风险降低(RR 0.71,95%CI 0.55-0.92;p=0.009)、全因死亡率降低(RR 0.80,0.66-0.96;p=0.014)和心血管死亡率降低(RR 0.71,0.50-0.99;p=0.044)相关。在纳入研究的一系列患者组中,这些效应似乎是一致的。
对于接受透析的个体,应常规考虑使用降低血压的药物进行治疗,以降低该人群非常高的心血管发病率和死亡率。